Drugs Made In America Acquisition reported net income of $1.73M for the quarter ended Jun 2026. This income statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 9.86M | 24.79M | 33.52M | 33.52M | 31.46M | 30.81M |
| Operating items | ||||||
| Selling, General & AdministrativeSG&A | 0.33M | 0.13M | 0.26M | 2.09M | 0.14M | |
| Operating ExpensesOpex | 0.33M | 0.13M | 0.26M | 2.09M | 0.14M | |
| Operating IncomeOp. Inc | -0.33M | -0.13M | -0.26M | -2.09M | -0.14M | |
| EBIT | -0.33M | -0.13M | -0.26M | -2.09M | -0.14M | |
| Non-operating items | ||||||
| Interest & Investment IncomeInt & Inv Inc | 1.59M | 2.42M | 2.45M | 2.30M | 1.86M | |
| Non Operating IncomeNon Op. Inc. | 2.42M | 2.45M | 2.30M | 1.86M | ||
| Net income details | ||||||
| EBT | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M | |
| Profit After TaxPAT | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M | |
| Income from Continuing OperationsIncome (Continuing) | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M | |
| Consolidated Net IncomeConsol Net Inc. | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M | |
| Income towards Parent CompanyParent Net Inc | 1.25M | 2.29M | 2.18M | 0.21M | 1.73M | |
| Net Income towards Common StockholdersNet Income | 0.77M | 1.57M | 1.50M | 0.15M | 1.13M | |
| Additional items | ||||||
| EPS (Basic) | 0.03 | 0.05 | 0.04 | 0.00 | 0.04 | |
| EPS (Diluted) | 0.03 | 0.05 | 0.04 | 0.00 | 0.04 | |
| Shares Outstanding | 8.57M | 24.79M | 33.52M | 33.52M | 31.46M | 30.81M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 8.57M | 25.51M | 33.52M | 33.52M | 31.64M | 30.81M |
| EBITDA | -0.33M | -0.13M | -0.26M | -2.09M | -0.14M |